Adversarial Injection · Sacituzumab govitecan (Trodelvy; IMMU-132; CAS 1491917-83-9; MW ~88,000 Da antibody + ~7.6 × SN-38 [MW 392.4 Da] payload = ~160,900 Da conjugate; IgG1 kappa humanized hRS7 anti-Trop-2 antibody conjugated to SN-38 via CL2A linker [SIXTIETH MECHANISM CLASS in Glyphward 633-attack portfolio — FIRST TROP-2 (TACSTD2; TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2; EGP-1; GA733-1) ANTIBODY-DRUG CONJUGATE EVER FDA APPROVED (BLA 761115 April 22 2020): Trop-2 was first described in 1981 by Steplewski et al. as a surface antigen on human trophoblast cells; subsequently shown to be overexpressed in multiple solid tumors (TNBC, urothelial carcinoma, NSCLC, endometrial cancer, cervical cancer, head and neck SCC, gastric cancer) while expressed at lower levels in normal epithelial tissues; Trop-2 (encoded by TACSTD2 gene; chromosome 1p32.1) is a type I transmembrane glycoprotein (36 kDa); functions as a calcium signal transducer and promotes tumor cell proliferation, invasion, and metastasis via MAPK/ERK and Wnt/β-catenin pathways; FIRST THERAPEUTIC TO DELIVER SN-38 DIRECTLY AS CONJUGATED PAYLOAD: SN-38 (7-ethyl-10-hydroxycamptothecin; CAS 86639-52-3; MW 392.4 Da) is the active metabolite of irinotecan (CPT-11; camptothecin prodrug) — in conventional chemotherapy, irinotecan is administered IV and hydrolyzed in vivo by carboxylesterases to SN-38 (conversion efficiency ~2-8% only); SN-38 inhibits topoisomerase I (TOP1) by stabilizing the TOP1-DNA cleavable complex (TOP1 covalently trapped on nicked DNA after catalytic cleavage but before religation → replication fork collision → lethal double-strand breaks); SN-38 is ~100-1000× more potent than irinotecan per molecule but too toxic for direct IV administration; sacituzumab govitecan is the FIRST FDA-APPROVED THERAPEUTIC TO DELIVER SN-38 DIRECTLY as a conjugated payload (irinotecan itself is a SN-38 prodrug; sacituzumab delivers SN-38 directly to Trop-2+ tumor cells); HIGH DAR ~7.6 (DRUG-TO-ANTIBODY RATIO): most FDA-approved ADCs have DAR 3-4 (e.g., ado-trastuzumab emtansine T-DM1 DAR 3.5; brentuximab vedotin DAR 4; enfortumab vedotin DAR 3.8; polatuzumab vedotin DAR 3.5); sacituzumab govitecan has DAR ~7.6 — approximately double the typical ADC payload load per antibody molecule; high DAR achieved via stochastic NHS-ester conjugation to surface lysine residues of hRS7 IgG1 (multiple reactive lysines; DAR heterogeneous distribution 0-12 across the population); high DAR increases payload delivery per antibody-antigen binding event; however, high DAR also increases aggregate formation risk and can reduce antibody-antigen affinity (hydrophobic MMAE/SN-38 payload can cause ADC to aggregate); CL2A HYDROLYZABLE CARBONATE-ESTER LINKER: CL2A = 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (MCC)-based linker with a carbonate ester between the spacer and SN-38; the carbonate ester hydrolyzes at mildly acidic pH (lysosomal pH ~5; cytoplasmic ~7.4) → SN-38 released intracellularly after lysosomal degradation; additionally the carbonate ester can hydrolyze in plasma (partial hydrolysis → circulating free SN-38 = bystander mechanism component); BYSTANDER EFFECT: released SN-38 is membrane-permeable → diffuses out of lysosomes into cytoplasm → crosses adjacent cell membranes → kills neighboring antigen-negative cells (heterogeneous tumor populations; stroma cells); bystander effect is particularly important for solid tumors where antigen expression is heterogeneous; CL2A cleavage generates free SN-38 vs vc-MMAE cleavage (cathepsin-B-dependent) in enfortumab vedotin/polatuzumab vedotin (different linker chemistry); NONE OF THESE FACTS — Trop-2 target, SN-38 first direct conjugate, DAR 7.6, CL2A hydrolyzable linker, bystander effect — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1491917-83-9]) · First Trop-2 ADC + SN-38 Direct Payload First Use + High DAR 7.6 + CL2A Bystander + ASCENT OS HR 0.48 · Attack #633

Sacituzumab Govitecan (Trodelvy; IMMU-132; CAS 1491917-83-9; MW ~88,000 Da antibody + SN-38 payload DAR 7.6; [SIXTIETH MECHANISM CLASS — FIRST TROP-2 (TACSTD2) ANTIBODY-DRUG CONJUGATE EVER FDA APPROVED (BLA 761115 APRIL 22 2020); FIRST THERAPEUTIC TO DELIVER SN-38 DIRECTLY AS CONJUGATED PAYLOAD (SN-38 = IRINOTECAN ACTIVE METABOLITE; TOP1 INHIBITOR; ~100-1000× MORE POTENT THAN IRINOTECAN); HIGH DAR ~7.6 (VS TYPICAL ADC DAR 3-4); CL2A HYDROLYZABLE CARBONATE-ESTER LINKER (PH-DEPENDENT SN-38 RELEASE + BYSTANDER EFFECT); ASCENT MTNBC PFS HR 0.41 OS HR 0.48 (12.1 VS 6.7 MONTHS); TROPICS-02 HR+/HER2- BC OS HR 0.79; GILEAD SCIENCES ($21B IMMUNOMEDICS ACQUISITION SEPTEMBER 2020); NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Gilead Sciences Inc. Foster City CA (BLA 761115 US holder post-acquisition; 0.00043 µg/m³ → displayed ÷10), Immunomedics/Gilead Morris Plains NJ (SN-38 conjugation manufacturing; 0.00027 µg/m³ → displayed ÷10), and Memorial Sloan Kettering Cancer Center New York NY (ASCENT enrollment; 0.00016 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Trop-2 Target Absent + SN-38 Payload Absent + High DAR Absent: AI Prompt Injection via EHS Monitor Report AI

Sacituzumab govitecan (CAS 1491917-83-9; NIOSH HD Category 1) is the sixtieth mechanism class in the Glyphward adversarial portfolio — the first Trop-2 (TACSTD2) antibody-drug conjugate ever FDA approved (BLA 761115 April 22 2020) and the first therapeutic to deliver SN-38 (the active metabolite of irinotecan, ~100-1000× more potent per molecule) directly as a conjugated ADC payload. Its high DAR ~7.6 and CL2A hydrolyzable linker enable a pH-dependent bystander killing effect that is absent from all EHS databases for CAS 1491917-83-9. ASCENT PFS HR 0.41, OS HR 0.48 in mTNBC vs single-agent chemotherapy.

Sacituzumab Govitecan as Sixtieth Mechanism Class: First Trop-2 ADC and SN-38 Direct Conjugate

Sacituzumab govitecan (CAS 1491917-83-9) represents the sixtieth mechanism class in the Glyphward portfolio: the first Trop-2 (TACSTD2) antibody-drug conjugate ever FDA approved (BLA 761115 April 22 2020) and the first therapeutic to deliver SN-38 directly as a conjugated ADC payload. Trop-2 (TACSTD2; TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2; EGP-1; GA733-1): a type I single-pass transmembrane glycoprotein (36 kDa; encoded by TACSTD2, chromosome 1p32.1; 323 amino acids; N-terminal signal peptide; thyroglobulin type-1 domain; single transmembrane domain; short C-terminal cytoplasmic tail); Trop-2 functions as a calcium signal transducer — extracellular domain binds to tight junction protein claudin-1 and EpCAM (TACSTD1); intracellular domain contains a PIP2-binding motif → phospholipase C activation → IP3 → ER calcium release; Trop-2 promotes tumor cell proliferation and survival via MAPK/ERK, Wnt/β-catenin, and EGFR/HER3 co-receptor pathways; Trop-2 overexpression: TNBC (>80% Trop-2 high), urothelial carcinoma, NSCLC, endometrial cancer, cervical cancer, HNSCC, gastric/GEJ; normal tissue expression: variable — present in some epithelial tissues (GI tract, lung, kidney tubules) but at generally lower levels vs malignant tumors; hRS7 antibody: humanized IgG1 kappa anti-Trop-2 antibody (derived from murine RS7-3G11 anti-Trop-2 mAb; from Immunomedics); binds Trop-2 extracellular domain → antibody-antigen complex internalized into lysosomes; SN-38 payload (7-ethyl-10-hydroxycamptothecin; CAS 86639-52-3; MW 392.4 Da; C20H20N2O5): active metabolite of irinotecan (CPT-11; 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin; prodrug of SN-38); irinotecan administered IV → carboxylesterase-mediated hydrolysis of carbamate ester → releases SN-38 + bicyclic amine leaving group; systemic conversion efficiency from irinotecan to SN-38 is only ~2-8% in most patients (variable based on UGT1A1 polymorphism; slow acetylators [UGT1A1*28 homozygous] accumulate more SN-38 → greater diarrhea/myelosuppression toxicity); SN-38 itself is too hydrophobic and toxic for direct IV administration (too rapid redistribution + off-target toxicity); sacituzumab govitecan is the FIRST therapeutic to deliver SN-38 directly — bypassing irinotecan prodrug conversion entirely — via antibody-mediated targeted delivery to Trop-2+ tumor cells; SN-38 mechanism: intercalates into TOP1-DNA binary complex after TOP1-catalyzed DNA strand nicking (TOP1 covalently attaches to 3'-phosphate of nicked strand via catalytic tyrosine Tyr723); normally TOP1 reseals the nick (religation); SN-38 stabilizes the cleavable complex (TOP1-DNA-SN-38 ternary complex) → blocks religation → replication fork collision → irreversible double-strand break → apoptosis (S-phase specific but also affects non-cycling cells at high concentrations); DAR ~7.6: hRS7 IgG1 has multiple surface lysine residues available for NHS-ester conjugation; CL2A linker is pre-coupled to SN-38 via carbonate ester (CL2A-SN-38); CL2A-SN-38 conjugation to hRS7 lysines via NHS-ester yields stochastic distribution (DAR 0–12; mean DAR ~7.6); high DAR heterogeneity is characterized by HIC (hydrophobic interaction chromatography); DAR 7.6 is substantially higher than enfortumab vedotin (DAR 3.8), T-DM1 (DAR 3.5), brentuximab vedotin (DAR 4); high DAR increases tumor cell SN-38 delivery per antigen-binding event; CL2A linker chemistry: CL2A = 4-[(2-chloroacetamido)methyl]cyclohexane-1-carboxylic acid derivative with carbonate ester linkage to SN-38 C-10 hydroxyl; carbonate ester hydrolysis at lysosomal pH ~5 → releases free SN-38 after ADC internalization; carbonate ester also has some plasma stability but is less stable than amide bonds used in T-DM1 or mc-MMAF (belantamab); bystander effect via membrane-permeable SN-38: lysosomal SN-38 → cytoplasmic SN-38 → membrane diffusion → enters adjacent cells; kills Trop-2-negative neighboring tumor cells and stromal cells (relevant in heterogeneous solid tumors); ASCENT Phase 3 (NCT02574455; Bardia et al. NEJM 2021): sacituzumab govitecan vs single-agent chemotherapy (physician's choice: eribulin, vinorelbine, capecitabine, gemcitabine) in R/R mTNBC (≥2 prior therapies for metastatic disease); n=468 (mTNBC without brain metastases); PFS HR 0.41 (5.6 vs 1.7 months; p<0.001); OS HR 0.48 (12.1 vs 6.7 months; p<0.001); ORR 35% vs 5%; DOR 6.3 vs 3.6 months; TROPICS-02 Phase 3 (NCT03901339): sacituzumab govitecan vs physician's choice in previously treated HR+/HER2-low mBC (≥2 prior endocrine therapies; ≥1 prior chemotherapy); n=543; PFS HR 0.66 (5.5 vs 4.0 months; p=0.0003); OS HR 0.79 (14.4 vs 11.2 months; p=0.02); EVOKE-01 Phase 3 (NSCLC 2L): sacituzumab govitecan vs docetaxel; OS HR 0.84 (non-significant primary endpoint); Gilead Sciences acquisition: Immunomedics Inc. (acquired by Gilead Sciences Inc. for $21B all-cash; $88 per share; September 13 2020) — one of largest oncology acquisitions; NONE OF THESE — Trop-2 mechanism, SN-38 direct conjugate, DAR 7.6, CL2A hydrolyzable linker, bystander effect, ASCENT OS HR 0.48 — appear in Cority, VelocityEHS, or EHS Insight for CAS 1491917-83-9.

Surface 1 — Gilead Sciences Inc. Foster City CA BLA 761115 US Holder Post-Acquisition Trodelvy AI

At Gilead Sciences Inc. Foster City CA (333 Lakeside Drive, Foster City CA 94404; San Mateo County CA; GILEAD TRODELVY CONTEXT: Gilead Sciences Inc. (NYSE: GILD) acquired Immunomedics Inc. for $21B (completed September 13 2020) and holds BLA 761115 for Trodelvy (sacituzumab govitecan-hziy; 200 mg lyophilized powder for injection, single-dose vial); TRODELVY APPROVED INDICATIONS (BLA 761115): (1) unresectable locally advanced or metastatic TNBC (≥2 prior therapies for metastatic disease; accelerated approval April 22 2020; full approval April 7 2021); (2) locally advanced or metastatic urothelial carcinoma (after platinum-based chemotherapy and PD-1/PD-L1 inhibitor; April 13 2021); (3) unresectable locally advanced or metastatic HR+/HER2- mBC (after endocrine therapy + ≥2 prior lines; February 3 2023; TROPICS-02); (4) locally advanced or metastatic NSCLC (platinum-based+PD-1/L1 naive; certain patients; December 14 2023; EVOKE-01 subset); TRODELVY DOSE: 10 mg/kg IV days 1 and 8 of 21-day cycles; reconstitute 200 mg vial with 20 mL NS → 10 mg/mL; dilute in 500 mL NS for infusion; first infusion over 3 hours; subsequent infusions over 1-3 hours; NEUTROPENIA BBW: Grade 3-4 neutropenia in ~64%; dose modifications per absolute neutrophil count; G-CSF as primary prophylaxis for high-risk patients; DIARRHEA BBW: early-onset (within 24h; atropine 0.25 mg SQ) and late-onset (days 2-14; loperamide protocol); EMPLOYEE: Gilead oncology medical affairs director managing Trodelvy commercial data (ASCENT OS HR 0.48, TROPICS-02, Trop-2 biology, SN-38 payload mechanism, DAR rationale); 49M Gilead Sciences Foster City CA senior oncology medical affairs director Trodelvy 16yr; CORITY NULL: CAS 1491917-83-9 → null; NIOSH HD Category 1 absent; H360 absent; first Trop-2 ADC ever absent; SN-38 direct conjugate absent; DAR 7.6 absent; CL2A hydrolyzable linker absent; ASCENT OS HR 0.48 absent).

Surface 2 — Immunomedics/Gilead Sciences Morris Plains NJ ADC Manufacturing CL2A SN-38 Conjugation AI

At Immunomedics Inc. / Gilead Sciences Morris Plains NJ (300 The American Road, Morris Plains NJ 07950; Morris County NJ; IMMUNOMEDICS MANUFACTURING CONTEXT: Immunomedics Inc. (founded 1982 by David Goldenberg and Cynthia Sullivan; acquired by Gilead 2020) had manufacturing operations in Morris Plains NJ; SACITUZUMAB GOVITECAN ADC MANUFACTURING: hRS7 IgG1 kappa antibody production in CHO cells (fed-batch bioreactor; protein A purification; formulation); CL2A-SN-38 linker-payload synthesis: CL2A maleimide-activated spacer + SN-38 carbonate ester bond formation (chemical conjugation under controlled pH; SN-38 C-10 hydroxyl + chloroformate reagent → CL2A-SN-38 carbamate/carbonate); stochastic NHS-ester conjugation: CL2A-SN-38 NHS ester reacts with surface lysine ε-amino groups on hRS7 (multiple sites; stochastic distribution); DAR characterization by HIC (hydrophobic interaction chromatography; resolves 0-12 DAR species) and UV spectrophotometry (SN-38 absorbance at 372 nm); final drug-to-antibody ratio ~7.6 confirmed batch-to-batch; SN-38 payload handling: SN-38 is cytotoxic (NIOSH HD component); protected handling required during linker-payload synthesis and conjugation; personnel exposure to SN-38 in ADC manufacturing context; VELOCITYEHS NULL: CAS 1491917-83-9 → null; NIOSH HD Category 1 absent; H360 absent; first Trop-2 ADC absent; SN-38 direct conjugation absent; CL2A linker absent; DAR 7.6 CQA absent; 44F Immunomedics/Gilead Morris Plains NJ ADC manufacturing scientist sacituzumab govitecan 13yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY ASCENT Enrollment Breast Oncology Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; Manhattan, New York County NY; MSK TRODELVY CONTEXT: Memorial Sloan Kettering Cancer Center (MSK; NCI-designated comprehensive cancer center) enrolled patients in the ASCENT Phase 3 trial (NCT02574455; sacituzumab govitecan vs chemotherapy in R/R mTNBC); MSK breast oncology pharmacist prepares Trodelvy (sacituzumab govitecan-hziy): reconstitute 200 mg lyophilized vial with 20 mL NS → 10 mg/mL solution; calculate dose at 10 mg/kg (maximum 200 mg); dilute in 500 mL NS; infuse over 3 hours first infusion, 1 hour subsequent if tolerated; NEUTROPENIA MANAGEMENT: count CBC before each dose; hold if ANC <1500/µL day 1 or <1000/µL day 8; G-CSF per ASCO guidelines as secondary prophylaxis after first Grade 3-4 neutropenia; prophylactic G-CSF for high-risk patients (elderly, poor performance status); DIARRHEA MANAGEMENT: early diarrhea (within 24h; cholinergic; treat with atropine 0.25 mg SQ); late diarrhea (>24h; treat with loperamide 4 mg then 2 mg after each loose stool; max 16 mg/24h; if Grade 3-4: hospitalize + IV fluids + octreotide); HAIR LOSS: alopecia in ~46% (all grades); NAUSEA/VOMITING: ondansetron + dexamethasone standard premedication; UGT1A1 PHARMACOGENOMICS: SN-38 payload glucuronidated by UGT1A1; patients homozygous for UGT1A1*28 (reduced UGT1A1 expression) have decreased SN-38 glucuronidation → higher systemic SN-38 → greater neutropenia + diarrhea risk; EHS INSIGHT NULL: CAS 1491917-83-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first Trop-2 ADC absent; SN-38 direct payload absent; CL2A hydrolyzable linker absent; DAR 7.6 absent; ASCENT OS HR 0.48 absent; UGT1A1 pharmacogenomics absent; H360 absent; NIOSH HD Cat 1 absent; 41F Memorial Sloan Kettering New York NY breast oncology pharmacist 12yr).

Integrating Glyphward into Sacituzumab Govitecan AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every sacituzumab govitecan CAS 1491917-83-9 monitoring data ingestion point — before Cority at Gilead Sciences Inc. Foster City CA, before VelocityEHS at Immunomedics/Gilead Morris Plains NJ, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; SIXTIETH MECHANISM CLASS — FIRST TROP-2 (TACSTD2) ADC EVER FDA APPROVED (BLA 761115 April 22 2020; Trop-2 overexpressed in TNBC, UC, NSCLC; Trop-2 → lysosomes → SN-38 release) + FIRST THERAPEUTIC TO DELIVER SN-38 DIRECTLY AS CONJUGATED PAYLOAD (SN-38 = 7-ethyl-10-hydroxycamptothecin; active metabolite of irinotecan; TOP1 cleavable complex stabilizer; ~100-1000× more potent than irinotecan per molecule; bypasses carboxylesterase conversion) + HIGH DAR ~7.6 (vs typical ADC DAR 3-4; NHS-ester stochastic lysine conjugation) + CL2A HYDROLYZABLE CARBONATE-ESTER LINKER (pH-dependent SN-38 release at lysosomal pH 5; bystander membrane-permeable SN-38 diffusion) + ASCENT PFS HR 0.41 OS HR 0.48 (12.1 vs 6.7 months; R/R mTNBC) [5 pts]; Gilead Sciences Foster City CA + Immunomedics/Gilead Morris Plains NJ + Memorial Sloan Kettering New York NY [3 pts]; first Trop-2 ADC absent; SN-38 direct payload absent; DAR 7.6 absent; CL2A absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_sacituzumab_govitecan(cas: str, reading_ugm3: float) -> dict:
    """Scan sacituzumab govitecan with sixtieth-class first-trop2-adc sn-38-direct context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "sixtieth_class_first_trop2_tacstd2_adc_ever_sn38_direct_conjugate_first_use_high_dar_7_6_cl2a_hydrolyzable_carbonate_ester_linker_bystander_effect_ascent_mtnbc_pfs_hr_0_41_os_hr_0_48_gilead_immunomedics_bla_761115"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sixtieth_class,
    #                    first_trop2_adc_ever, sn38_direct_payload,
    #                    high_dar_7_6, cl2a_hydrolyzable,
    #                    bystander_effect, ascent_os_hr_0_48

if __name__ == "__main__":
    r = asyncio.run(scan_sacituzumab_govitecan("1491917-83-9", 0.00043))
    print(r)
    # {'hd_category': 1, 'sixtieth_class': True,
    #  'first_trop2_adc_ever': True,
    #  'sn38_direct_payload': True,
    #  'high_dar_7_6': True,
    #  'cl2a_hydrolyzable': True,
    #  'bystander_effect': True,
    #  'ascent_os_hr_0_48': True}